Targeting 6-Phosphofructo-2-Kinase (PFKFB3) as a Therapeutic Strategy against Cancer

作者
Brian F. Clem,Julie O’Neal,Gilles H. Tapolsky,Amy L. Clem,Yoannis Imbert-Fernandez,Daniel Alan Kerr,Alden C. Klarer,Rebecca Ann Redman,Donald Max Miller,John O. Trent,Sucheta Telang,Jason Alan Chesney
出处
期刊:Molecular Cancer Therapeutics [American Association for Cancer Research]
卷期号:12 (8): 1461-1470 被引量:277
标识
DOI:10.1158/1535-7163.mct-13-0097
摘要

In human cancers, loss of PTEN, stabilization of hypoxia inducible factor-1α, and activation of Ras and AKT converge to increase the activity of a key regulator of glycolysis, 6-phosphofructo-2-kinase (PFKFB3). This enzyme synthesizes fructose 2,6-bisphosphate (F26BP), which is an activator of 6-phosphofructo-1-kinase, a key step of glycolysis. Previously, a weak competitive inhibitor of PFKFB3, 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO), was found to reduce the glucose metabolism and proliferation of cancer cells. We have synthesized 73 derivatives of 3PO and screened each compound for activity against recombinant PFKFB3. One small molecule, 1-(4-pyridinyl)-3-(2-quinolinyl)-2-propen-1-one (PFK15), was selected for further preclinical evaluation of its pharmacokinetic, antimetabolic, and antineoplastic properties in vitro and in vivo. We found that PFK15 causes a rapid induction of apoptosis in transformed cells, has adequate pharmacokinetic properties, suppresses the glucose uptake and growth of Lewis lung carcinomas in syngeneic mice, and yields antitumor effects in three human xenograft models of cancer in athymic mice that are comparable to U.S. Food and Drug Administration-approved chemotherapeutic agents. As a result of this study, a synthetic derivative and formulation of PFK15 has undergone investigational new drug (IND)-enabling toxicology and safety studies. A phase I clinical trial of its efficacy in advanced cancer patients will initiate in 2013 and we anticipate that this new class of antimetabolic agents will yield acceptable therapeutic indices and prove to be synergistic with agents that disrupt neoplastic signaling.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
颜庸完成签到,获得积分10
1秒前
酷波er的应助被小王小王采纳,获得10
1秒前
陌笙完成签到,获得积分10
1秒前
yoshlpzxr完成签到,获得积分10
1秒前
2秒前
我是谁的应助被LucyHarris108采纳,获得40
3秒前
Kevin发布了新的文献求助10
3秒前
now完成签到,获得积分10
3秒前
梨花香发布了新的文献求助50
3秒前
科研通AI2S的应助被另一种蓝色采纳,获得10
4秒前
在水一方的应助被笙笙采纳,获得10
4秒前
苗条故事关注了科研通微信公众号
4秒前
CipherSage的应助被Kevin采纳,获得10
4秒前
刘国良完成签到 ,获得积分10
5秒前
kangkang发布了新的文献求助10
5秒前
完完全全1完成签到,获得积分10
6秒前
7秒前
7秒前
Harry发布了新的文献求助10
8秒前
汉堡包的应助被pancake采纳,获得50
8秒前
慕青的应助被PP采纳,获得10
9秒前
111完成签到,获得积分10
9秒前
10秒前
10秒前
11秒前
11秒前
11秒前
英姑的应助被灝男采纳,获得30
12秒前
爱笑海亦发布了新的文献求助10
12秒前
13秒前
13秒前
小淡发布了新的文献求助10
13秒前
amy发布了新的文献求助10
13秒前
13秒前
14秒前
科研通AI6.4的应助被简单老师采纳,获得10
14秒前
14秒前
西贡老王关注了科研通微信公众号
16秒前
完完全全1发布了新的文献求助10
16秒前
111发布了新的文献求助10
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8177802
求助须知:如何正确求助?哪些是违规求助? 9568632
关于积分的说明 21799933
捐赠科研通 7772424
什么是DOI,文献DOI怎么找? 3432505
关于科研通互助平台的介绍 2556698
邀请新用户注册赠送积分活动 2478055